Most Read Articles
Roshini Claire Anthony, 5 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Stephen Padilla, 6 days ago
Implementation of the collaborative care in a rheumatoid arthritis (RA) clinic has led to improvements in nonbiologic disease-modifying antirheumatic drugs (nb-DMARDs) optimization, adherence to safety recommendations on nb-DMARD monitoring and detection of adverse drug events in RA patients, according to a Singapore study.
Pearl Toh, 6 days ago
Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.
5 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.

Dupilumab, cyclosporine proven safe, effective for severe atopic dermatitis

27 Jan 2019

Current evidence shows dupilumab and cyclosporine as effective treatment for severe atopic dermatitis (AD), reports a recent systematic review, adding that long-term safety and efficacy of biologic medications require further research.

Forty-one studies met the eligibility criteria and were included in the final analysis. Evidence showed consistent improvements with dupilumab and cyclosporine in Eczema Area and Severity Index and Scoring Atopic Dermatitis.

Lebrikizumab and tralokinumab showed efficacy in phase II clinical trials; phase III trials were thus warranted. Furthermore, there were no studies that reported on the efficacy of such biologic medications in paediatric patients, but cyclosporine improved clinical severity by the greatest amount in this population.

An earlier study reported the efficacy and safety of dupilumab for the treatment of moderate-to-severe AD in adults, supporting its role as a primary targeted biologic medication in adult patients with moderate-to-severe AD. [Oncotarget 2017;8:108480-108491]

Another study suggested that dupilumab is “currently the only biologic [treatment] with robust evidence of efficacy in AD. Other medications (eg, nemolizumab, lebrikizumab and tralokinumab) are promising but require further data. [Am J Clin Dermatol 2018;19:145-165]

The current systematic review accessed Medline, Ovid and Embase databases to compare efficacies of systemic therapies for the treatment of AD. Included were randomized controlled trials that analysed the efficacy of systemic treatments for AD in adults and children.

The study was limited by its lack of well controlled comparison studies that made direct comparisons between treatments difficult.

“Systemic medications are often required for severe AD refractory to topical therapies. Biologic medications are a recent advancement in the field and a comparison with standard systemic approaches would be beneficial,” the authors said.

Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Stephen Padilla, 6 days ago
Implementation of the collaborative care in a rheumatoid arthritis (RA) clinic has led to improvements in nonbiologic disease-modifying antirheumatic drugs (nb-DMARDs) optimization, adherence to safety recommendations on nb-DMARD monitoring and detection of adverse drug events in RA patients, according to a Singapore study.
Pearl Toh, 6 days ago
Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.
5 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.